Schizophrenia - Pipeline Review, H1 2016

Description: Schizophrenia - Pipeline Review, H1 2016

Summary

The report ‘Schizophrenia - Pipeline Review, H1 2016’, provides an overview of the Schizophrenia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Schizophrenia
- The report reviews pipeline therapeutics for Schizophrenia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Schizophrenia therapeutics and enlists all their major and minor projects
- The report assesses Schizophrenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Schizophrenia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Schizophrenia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus
of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:
Introduction
Schizophrenia Overview
Therapeutics Development
Schizophrenia - Therapeutics under Development by Companies
Schizophrenia - Therapeutics under Investigation by Universities/Institutes
Schizophrenia - Pipeline Products Glance
Schizophrenia - Products under Development by Companies
Schizophrenia - Products under Investigation by Universities/Institutes
Schizophrenia - Companies Involved in Therapeutics Development
Schizophrenia - Therapeutics Assessment
Drug Profiles
Schizophrenia - Recent Pipeline Updates
Schizophrenia - Dormant Projects
Schizophrenia - Discontinued Products
Schizophrenia - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Schizophrenia, H1 2016
Number of Products under Development for Schizophrenia - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Development by Companies, H1 2016 (Contd..2)
Number of Products under Development by Companies, H1 2016 (Contd..3)
Number of Products under Development by Companies, H1 2016 (Contd..4)
Number of Products under Development by Companies, H1 2016 (Contd..5)
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Development by Companies, H1 2016 (Contd..3)
Products under Development by Companies, H1 2016 (Contd..4)
Products under Development by Companies, H1 2016 (Contd..5)
Products under Development by Companies, H1 2016 (Contd..6)
Products under Development by Companies, H1 2016 (Contd..7)
Products under Development by Companies, H1 2016 (Contd..8)
Products under Development by Companies, H1 2016 (Contd..9)
Products under Investigation by Universities/Institutes, H1 2016
Schizophrenia - Pipeline by AbbVie Inc., H1 2016
Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc., H1 2016
Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc., H1 2016
Schizophrenia - Pipeline by Aestus Therapeutics, Inc., H1 2016
Schizophrenia - Pipeline by AgeneBio Inc., H1 2016
Schizophrenia - Pipeline by Alkermes Plc, H1 2016
Schizophrenia - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016
Schizophrenia - Pipeline by Amgen Inc., H1 2016
Schizophrenia - Pipeline by Angita B.V., H1 2016
Schizophrenia - Pipeline by Astellas Pharma Inc., H1 2016
Schizophrenia - Pipeline by AstraZeneca Plc, H1 2016
Schizophrenia - Pipeline by Athyrsys, Inc., H1 2016
Schizophrenia - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2016
Schizophrenia - Pipeline by BCWorld Pharm Co. Ltd., H1 2016
Schizophrenia - Pipeline by BioCrea GmbH, H1 2016
Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H1 2016
Schizophrenia - Pipeline by Braeburn Pharmaceuticals, Inc., H1 2016
Schizophrenia - Pipeline by Bristol-Myers Squibb Company, H1 2016
Schizophrenia - Pipeline by Coronis Partners Ltd., H1 2016
Schizophrenia - Pipeline by Critical Pharmaceuticals Limited, H1 2016
Schizophrenia - Pipeline by Curemark, LLC, H1 2016
Schizophrenia - Pipeline by Delpor, Inc., H1 2016
Schizophrenia - Pipeline by Echo Pharmaceuticals B.V., H1 2016
Schizophrenia - Pipeline by Egis Gyogyszergyar Nyrt, H1 2016
Schizophrenia - Pipeline by Eli Lilly and Company, H1 2016
Schizophrenia - Pipeline by Evotec AG, H1 2016
Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
Schizophrenia - Pipeline by FORUM Pharmaceuticals Inc., H1 2016
Schizophrenia - Pipeline by Galenea Corp., H1 2016
Schizophrenia - Pipeline by GeNeuro SA, H1 2016
Schizophrenia - Pipeline by Gilead Sciences, Inc., H1 2016
Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016
Schizophrenia - Pipeline by GP Pharm, S.A., H1 2016
Schizophrenia - Pipeline by GW Pharmaceuticals Plc, H1 2016
Schizophrenia - Pipeline by H. Lundbeck A/S, H1 2016
Schizophrenia - Pipeline by Heptares Therapeutics Limited, H1 2016
Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2016
Schizophrenia - Pipeline by Indivior Plc, H1 2016
Schizophrenia - Pipeline by INSYS Therapeutics, Inc., H1 2016
Schizophrenia - Pipeline by Integrative Research Laboratories Sweden AB, H1 2016
Schizophrenia - Pipeline by IntelGenx Corp., H1 2016
Schizophrenia - Pipeline by Intra-Cellular Therapies, Inc., H1 2016
Schizophrenia - Pipeline by Iproteos S.L., H1 2016
Schizophrenia - Pipeline by Jiangsu Nhwa Pharmaceutical Corporation Ltd., H1 2016
Schizophrenia - Pipeline by Johnson & Johnson, H1 2016
Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc., H1 2016
Schizophrenia - Pipeline by KemPharm, Inc., H1 2016
Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H1 2016
Schizophrenia - Pipeline by Lead Discovery Center GmbH, H1 2016
Schizophrenia - Pipeline by Lohocla Research Corporation, H1 2016
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luc Therapeutics, Inc.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Luye Pharma Group Ltd.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Mapi Pharma Ltd.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Merck &amp; Co., Inc.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Mitsubishi Tanabe Pharma Corporation</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Neuralstem, Inc.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Neurocrine Biosciences, Inc.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>NeurOp, Inc,</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Newron Pharmaceuticals S.p.A.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Omeros Corporation</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Otsuka Holdings Co., Ltd.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Pepron, Inc.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Pfizer Inc.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Promentis Pharmaceuticals, Inc.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Reviva Pharmaceuticals Inc.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Richter Gedeon Nyrt.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Saniona AB,</td>
<td>H1 2016</td>
</tr>
<tr>
<td>SK Biopharmaceuticals Co., Ltd.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Spherium Biomed S.L.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Sumitomo Dainippon Pharma Co., Ltd.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Sunovion Pharmaceuticals Inc.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Suven Life Sciences Ltd.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Taisho Pharmaceutical Holdings Co., Ltd.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Company Limited</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Tetra Discovery Partners LLC</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Teva Pharmaceutical Industries Ltd.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Vanda Pharmaceuticals Inc.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Zogenix, Inc.</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Zysis Limited</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Monotherapy Products</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Combination Products</td>
<td>H1 2016</td>
</tr>
<tr>
<td>Number of Products by Stage and Target</td>
<td>H1 2016</td>
</tr>
</tbody>
</table>
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Schizophrenia Therapeutics - Recent Pipeline Updates, H1 2016
Schizophrenia - Dormant Projects, H1 2016
Schizophrenia - Dormant Projects (Contd..1), H1 2016
Schizophrenia - Dormant Projects (Contd..2), H1 2016
Schizophrenia - Dormant Projects (Contd..3), H1 2016
Schizophrenia - Dormant Projects (Contd..4), H1 2016
Schizophrenia - Dormant Projects (Contd..5), H1 2016
Schizophrenia - Dormant Projects (Contd..6), H1 2016
Schizophrenia - Dormant Projects (Contd..7), H1 2016
Schizophrenia - Dormant Projects (Contd..8), H1 2016
Schizophrenia - Dormant Projects (Contd..9), H1 2016
Schizophrenia - Dormant Projects (Contd..10), H1 2016
Schizophrenia - Dormant Projects (Contd..11), H1 2016
Schizophrenia - Dormant Projects (Contd..12), H1 2016
Schizophrenia - Dormant Projects (Contd..13), H1 2016
Schizophrenia - Dormant Projects (Contd..14), H1 2016
Schizophrenia - Discontinued Products, H1 2016
Schizophrenia - Discontinued Products (Contd..1), H1 2016
Schizophrenia - Discontinued Products (Contd..2), H1 2016
Schizophrenia - Discontinued Products (Contd..3), H1 2016
Schizophrenia - Discontinued Products (Contd..4), H1 2016
Schizophrenia - Discontinued Products (Contd..5), H1 2016
List of Figures
Number of Products under Development for Schizophrenia, H1 2016
Number of Products under Development for Schizophrenia - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016

Ordering:

Order Online - http://www.researchandmarkets.com/reports/3766795/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Schizophrenia - Pipeline Review, H1 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/3766795/">http://www.researchandmarkets.com/reports/3766795/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCPLCVFJ</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Electronic (PDF) - Single User:</th>
<th>USD 2000</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Electronic (PDF) - Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td></td>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World